SMShujiro Minami

Shujiro Minami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shujiro Minami has a total of 186 co-authors. Here are the top co-authors by number of shared publications:

  • Kimitaka Kaga

    Cochlear Implant Center, NHO Tokyo Medical Center, Tokyo, Japan; National Institute of Sensory Organs, NHO Tokyo Medical Center, Tokyo, Japan

    8 shared publications
  • Akira Ohkoshi

    Department of Otorhinolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan

    5 shared publications
  • Naomi Kiyota

    Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, Kobe, Japan

    5 shared publications
  • Akihiro Homma

    Department of Otolaryngology-Head & Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-Ku, N15W7, Sapporo 0608638, Hokkaido, Japan

    4 shared publications
  • Naoki Nishio

    Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    4 shared publications
  • Naoki Oishi

    Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Keio University, Tokyo

    4 shared publications

Latest Publications

  • Open Access

    Real-world performance of a Japanese browser-based hearing test: large-scale online usage data and concordance with clinical speech audiometry

    by Shujiro Minami, Marie Shimanuki, Takanori Nishiyama, Hiroshi Nishimura, Masaru Tateda, Ken Kato, Haruo Yoshida, Hiroyuki Sasaki, Satoko Shimizu, Naohiro Wakisaka, et al.

    Browser-based hearing tests offer a scalable alternative to clinic-based assessment, but most validated tools have been developed in English-speaking populations. The authors conducted a retrospective observational analysis of real-world use of a Japanese browser-based hearing test platform (April 2023–March 2026), complemented by a prospective multicentre paired sub-study against conventional clinical speech audiometry. The retrospective analysis included 8,022 unique users and 86,959 test executions across four modules: music perception (Montreal Battery of Evaluation of Musical Abilities); speech perception in quiet; speech in noise at +10, +5, and 0 dB signal-to-noise ratios (SNRs); and consonant identification. Completion rates of the full-length modules ranged from 43.7% to 85.8%. Speech perception in quiet showed pronounced upper-end clustering (41.0% of completed attempts and 57.9% of users scored ≥90%), whereas music perception was more broadly distributed (20.8% and 21.2%, ≥90%), and speech-in-noise accuracy fell progressively from a mean of 72.0% at +10 dB to 57.0% at 0 dB SNR, where no attempt reached 90%. These patterns persisted when the analysis was restricted to one attempt per user. Music perception correlated only modestly with all speech-related outcomes (Spearman ρ = 0.31–0.39). Repeat administration by the same user yielded intraclass correlation coefficients of 0.58–0.85 and a smallest detectable change of 17.6–35.8 percentage points. In the sub-study, 41 participants (25 unaided, 16 aided) completed the conventional 20-item 67-S word recognition test in a calibrated booth and, within days to weeks, the 20-item online check unsupervised on their own device. Agreement was moderate (Pearson r = 0.65, 95% CI [0.43, 0.80]; ICC(2,1) = 0.62, 95% CI [0.37, 0.78]), with a small negative bias (−6.2 percentage points, 95% CI [−10.8, −1.6]) and wide limits of agreement (−34.7 to +22.2). These data characterize the concordance of a non-English digital hearing assessment platform with clinical speech audiometry and provide the first estimates of its measurement error. They do not establish screening accuracy: no pure-tone reference, referral threshold, sensitivity, or specificity was evaluated, and the limits of agreement are too wide for individual-level clinical interpretation.

  • Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer

    by Makoto Tahara, Naomi Kiyota, Takeshi Kodaira, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Yuji Hirayama, Yusuke Onozawa, Naoki Nishio, Nobuhiro Hanai, et al.

    The interim analysis of JCOG1008 demonstrated that chemoradiotherapy with cisplatin 40 mg/m 2 once a week for seven cycles (weekly cisplatin) was noninferior in terms of overall survival (OS) compared with chemoradiotherapy with cisplatin 100 mg/m 2 once every 3 weeks for three cycles (3-weekly cisplatin) for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). This report presents the long-term follow-up results of JCOG1008. In this phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin or with weekly cisplatin. A total of 261 patients were enrolled. At the final analysis, with a median follow-up of 5.6 years, 5-year OS was 58.7% in the 3-weekly arm and 71.2% in the weekly arm (hazard ratio, 0.76 [95% CI, 0.52 to 1.12 [<1.32]]), confirming the noninferiority of the weekly regimen. Both 5-year relapse-free survival (RFS) and 5-year local RFS were numerically better in the weekly arm. No late adverse event showed more than a 10% difference between the two arms. In conclusion, 5-year follow-up confirmed that chemoradiotherapy with weekly cisplatin is noninferior in OS to chemoradiotherapy with 3-weekly cisplatin in patients with postoperative high-risk LA-SCCHN. These results further support the use of weekly cisplatin plus radiotherapy as a reasonable alternative for this patient population.


  • Risk factors for aspiration pneumonia related to postoperative chemoradiotherapy for high-risk head and neck cancer: A supplementary analysis of a phase II/III JCOG1008 trial

    by Tomoya Yokota, Naomi Kiyota, Takeshi Kodaira, Hiroshi Nishino, Ayako Nakanome, Yuji Hirayama, Naoki Nishio, Akira Ohkoshi, Kaoru Tanaka, Nobuya Monden, et al.


  • Open Access

    Retrospective study of definitive therapy for head and neck mucosal melanoma: The RESUME study

    by Motoo Nomura, Naomi Kiyota, Yasushi Shimizu, Atsushi Motegi, Tetsuo Akimoto, Takashi Mukaigawa, Takashi Fujii, Nayuta Tsushima, Kiyoto Shiga, Taiji Koyama, et al.


  • Open Access

    Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008

    by Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Takeshi Kodaira, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Shigemichi Iwae, Naoki Nishio, et al.

    Background: In a randomized phase II/III trial (JCOG1008), weekly cisplatin (40 mg/m2) was non‐inferior to 3‐weekly cisplatin (100 mg/m2) for postoperative high‐risk head and neck cancer. We investigated how acute kidney injury (AKI), a major dose‐limiting toxicity effect of cisplatin, affects overall survival (OS).Methods: We analyzed 251 patients from JCOG1008 receiving chemoradiotherapy. AKI was defined based on AKI Network criteria (serum creatinine increase of ≥0.3 mg/dL or ≥1.5‐fold [≥ stage I]) within 30 days after completing chemoradiotherapy. OS in the two arms was compared according to AKI development using the log‐rank test.Results: The total incidence of AKI was lower in the weekly arm than in the 3‐weekly arm (38/122 [31.1%] vs. 56/129 [43.4%]). Additionally, stage II/III AKI occurred less frequently in the weekly arm than in the 3‐weekly arm (8/122 [6.6%] vs. 19/129 [14.7%]). Cisplatin doses were similar in the weekly arm for patients with and without AKI (median, 238.6 mg/m2 vs. 239.2 mg/m2; p = 0.94), but lower in the 3‐weekly arm for those who developed AKI (median, 276.3 mg/m2 vs. 297.4 mg/m2; p = 0.007). In the weekly arm, there was no difference in OS between patients with and without AKI (hazard ratio [HR], 1.06; 95% confidence interval [CI], 0.53 to 2.10). However, in the 3‐weekly arm, patients with AKI had poorer OS than those without AKI (HR, 1.83; 95% CI, 1.04 to 3.21).Conclusions: In this supplementary analysis of JCOG1008 data, AKI impacted the OS of patients with head and neck cancer undergoing postoperative chemoradiotherapy in the 3‐weekly arm but not in the weekly arm. Our results further endorse the utilization of weekly cisplatin at 40 mg/m2 in this setting.


  • Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008

    by Hidetoshi Shimizu, Takeshi Kodaira, Naomi Kiyota, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Yuuji Hirayama, Yusuke Onozawa, Naoki Nishio, et al.


  • The error patterns of phonemes in children with prelingual hearing loss: A comparison between hearing aid and cochlear implant users

    by Yuri Nishiyama, Shujiro Minami, Ryoko Ijuin, Tomoko Kuroki, Ayako Tendo, Yuko Kusui, Satoko Wakabayashi, Kimitaka Kaga


  • Prediction of Cochlear Implant Effectiveness With Surface-Based Morphometry

    by Shujiro Minami, Masahiro Takahashi, Seiichi Shinden, Kyoko Shirai, Naoki Oishi, Hiroshi Nishimura, Masatsugu Masuda, Sawako Masuda, Takanori Nishiyama, Makoto Hosoya, et al.

    Objective: This study aimed to determine whether surface-based morphometry of preoperative whole-brain three-dimensional T1-weighted magnetic resonance imaging (MRI) images can predict the clinical outcomes of cochlear implantation. Study Design: This was an observational, multicenter study using preoperative MRI data. Setting: The study was conducted at tertiary care referral centers. Patients: Sixty-four patients with severe to profound hearing loss (≥70 dB bilaterally), who were scheduled for cochlear implant (CI) surgery, were enrolled. The patients included 19 with congenital hearing loss and 45 with acquired hearing loss. Interventions: Participants underwent CI surgery. Before surgery, high-resolution three-dimensional T1-weighted brain MRI was performed, and the images were analyzed using FreeSurfer. Main Outcome Measures: The primary outcome was monosyllable audibility under quiet conditions 6 months after surgery. Cortical thickness residuals within 34 regions of interest (ROIs) as per the Desikan-Killiany cortical atlas were calculated based on age and healthy-hearing control regression lines. Results: Rank logistic regression analysis detected significant associations between CI effectiveness and five right hemisphere ROIs and five left hemisphere ROIs. Predictive modeling using the cortical thickness of the right entorhinal cortex and left medial orbitofrontal cortex revealed a significant correlation with speech discrimination ability. This correlation was higher in patients with acquired hearing loss than in those with congenital hearing loss. Conclusions: Preoperative surface-based morphometry could potentially predict CI outcomes and assist in patient selection and clinical decision making. However, further research with larger, more diverse samples is necessary to confirm these findings and determine their generalizability.


  • Open Access

    A High Risk of Missing Congenital Cytomegalovirus-Associated Hearing Loss through Newborn Hearing Screening in Japan

    by Shujiro Bando Minami, Yoshiharu Yamanobe, Atsuko Nakano, Hirokazu Sakamoto, Sawako Masuda, Tetsuya Takiguchi, Sayaka Katsunuma, Tomoko Sugiuchi, Noriko Morita, Kimitaka Kaga, et al.

    It remains unclear to what extent newborn hearing screening (NHS) detects congenital cytomegalovirus (cCMV)-associated sensorineural hearing loss (SNHL) in Japan. This study aimed to clarify the NHS results and audiological characteristics of patients with cCMV-associated SNHL. A total of 541 individuals with unilateral or bilateral hearing loss of unknown etiology were examined for cCMV infection. cCMV infection was defined by the presence of CMV DNA in the dried umbilical cord detected using real-time quantitative PCR. NHS results and audiological data were retrospectively obtained from medical records. Forty-four cases (8.1%) were positive for cCMV infection. Of them, 33 cases underwent NHS and 13 cases (39.4%) passed NHS bilaterally. The pure-tone audiograms of 21 patients were obtained. There were seven cases of unilateral SNHL, five cases of asymmetric bilateral SNHL, and nine cases of symmetric bilateral SNHL. cCMV-related hearing loss is highly heterogeneous, and there is a high risk of missing this condition through NHS.